Atomoxetine Not Working? Why Strattera Might Not Be Helping Your ADHD

Atomoxetine (Strattera) is the most widely prescribed non-stimulant ADHD medication, but it doesn't work for everyone. If you've been taking it and aren't seeing the improvements in focus, attention, or impulse control you were expecting, you're far from alone. The reasons range from simple timing issues to something written into your DNA.

Unlike Adderall or Ritalin, which can work within hours, atomoxetine needs weeks to build up. Full effects often take 4 to 6 weeks, and some people don't hit peak benefit until 8 to 12 weeks. If you've just switched from a stimulant, the slower onset can feel like nothing is happening.

Atomoxetine is usually started at 40 mg/day and can be increased to 80 mg or even 100 mg. A lot of people end up underdosed because titration was too cautious or stopped too early. Your doctor may need to push the dose higher before deciding the drug doesn't work for you.

Atomoxetine works differently than stimulants. There's no immediate 'switch-on' effect. The improvement is gradual, mostly in sustained attention and emotional regulation. A lot of people don't notice the change until they look back over several weeks and realize things have actually shifted.

Common side effects like nausea, decreased appetite, and fatigue tend to be worst in the first few weeks, which is exactly when you're trying to figure out whether the drug is helping. They usually ease with time, but they make it hard to judge efficacy early on.

Among ADHD medications, atomoxetine has one of the clearest gene-drug relationships.^[1] Roughly 40% of people carry CYP2D6 variants that meaningfully change how the drug is cleared.

If you're an ultrarapid metabolizer, your body may clear atomoxetine so quickly that standard doses never build up to therapeutic levels. That's one of the most common genetic reasons the drug appears to 'not work.' At the other end of the spectrum, poor metabolizers break down atomoxetine very slowly, which leads to much higher blood levels. That can mean more side effects (faster heart rate, higher blood pressure, insomnia), but it can also mean better ADHD symptom control for people who can tolerate the higher levels. CPIC guidelines recommend plasma concentration monitoring and dose adjustments based on metabolizer status.^[1] Gene2Rx checks CYP2D6 and flags your metabolizer phenotype, so you and your prescriber can work from data rather than guesswork.^[3]

Pharmacogenetic testing is particularly useful for atomoxetine because CYP2D6 status has such a big effect on drug levels. If you've been on an adequate dose for at least 6 weeks without improvement, or you're getting bad side effects even at low doses, testing can tell you whether your metabolism is the problem. With that information your doctor can either adjust the dose or decide a different medication class is a better fit.

• 23andMe Pharmacogenetics: How to Get a Drug Response Report From Your Existing Data
• AncestryDNA for Drug Testing: Get Pharmacogenetics From Your Ancestry Data
• MyHeritage Pharmacogenetics: Use Your MyHeritage DNA for a Drug Response Report
• Nebula Genomics Pharmacogenetics: How to Get a Drug Response Report From Your WGS Data
• How Much Does a Pharmacogenetic Test Cost? 2026 Prices and Cheaper Alternatives
• Fibromyalgia Medication Not Working? How Genetics Affects Your Treatment Options

Atomoxetine is a norepinephrine reuptake inhibitor, not a stimulant. It raises norepinephrine in the brain rather than dopamine. It takes longer to work (weeks vs. hours) but gives 24-hour coverage without the abuse potential of stimulants.

It means your CYP2D6 enzyme works much slower than average at breaking down certain drugs, including atomoxetine. The drug builds up to higher levels in your blood, which usually shows up as more side effects. About 5-10% of people of European descent are poor metabolizers.

Some doctors do prescribe atomoxetine alongside a stimulant, but only with careful supervision. The combination hits different neurotransmitter systems, which can be complementary, but it also raises the risk of cardiovascular side effects.